Overview

Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

This is a prospective, single-center, randomize-controlled study. The purpose of this study is to evaluate the efficacy of neoadjuvant CDK4/6 inhibitors in patients with high-risk EPclin multigene risk analysis and non-response to Ki-67 2W, and to explore predictive biomarkers for sensitivity to CDK4/6 inhibitor therapy.

Phase:

PHASE2

Details

Lead Sponsor:

Peking University

Treatments:

dalpiciclib
Letrozole